Alnylam Pharmaceuticals (ALNY) EV to EBITDA (2009 - 2026)

Alnylam Pharmaceuticals (ALNY) EV to EBITDA (2009 - 2026) Analysis & Trends

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EV to EBITDA
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-	-852,542.90
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-	-155,086.11
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	-34,369.83
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn	680.60
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn	24.45
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn	16.40
7	Belite Bio	61.40 Bn	61.40 Bn	-	-3.48
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn	43.50
9	Revolution Medicines	37.37 Bn	37.37 Bn	-	-26.95
10	Alnylam Pharmaceuticals	36.08 Bn	33.07 Bn	959.66 Mn	43.97

Download Data